24 Participants NeededMy employer runs this trial

Povorcitinib + Ruxolitinib for Healthy Subjects

IC
IC
Overseen ByIncyte Corporation Call Center (ex-US)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.

Who Is on the Research Team?

IM

Incyte Medical Monitor

Principal Investigator

Incyte Corporation

Are You a Good Fit for This Trial?

This trial is for healthy adults aged 18 to 65 with a BMI between 18.0 and 30.5, no significant health issues, able to swallow pills, willing to avoid pregnancy during the study, and able to give informed consent.

Inclusion Criteria

I understand the study and am willing to sign a consent form.
I am between 18 and 65 years old.
My body mass index is between 18.0 and 30.5.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive multiple doses of oral povorcitinib or topical ruxolitinib cream

12 days
Daily visits for dosing and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

16 days
1-2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Povorcitinib
  • Ruxolitinib Cream

Trial Overview

The study compares how the body absorbs and processes multiple doses of an oral drug (povorcitinib) versus a topical cream (ruxolitinib) in healthy volunteers using special monitoring devices.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Cohort 3: PovorcitinibExperimental Treatment1 Intervention
Group II: Cohort 2: PovorcitinibExperimental Treatment1 Intervention
Group III: Cohort 1: Ruxolitinib 1.5 % CreamExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Incyte Corporation

Lead Sponsor

Trials
408
Recruited
66,800+
Steven Stein profile image

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot profile image

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School